BioNTech's take on iza-bren enters the clinic
The latest projects newly into human trials include BNT3212.
Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
MacroGenics faces new competition
Duality takes its Adam9-targeting conjugate into the clinic.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
Colorectal cancer is next for VEGF bispecifics
Pumitamig is the latest to be tested in first-line disease.
A new multiple myeloma race heats up
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
